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Chronic liver disease is a major cause of morbidity and mortality worldwide. More than 3 
million patients are infected with chronic hepatitis C which, when left untreated, can result in 
liver cirrhosis, liver transplantation, hepatocellular carcinoma, and early mortality. Successful 
treatment of hepatitis C can dramatically reduce these risks, however the high cost of treatment 
may limit its use. Similarly, surgical intervention can be curative for patients with hepatocellular 
carcinoma, however nonclinical barriers may limit access to surgical intervention for medically 
eligible patients. The papers in this dissertation evaluated methods of improving access to and 
equitable utilization of available treatment options to interrupt the continuum of chronic liver 
disease. First, we compared the cost-effectiveness of two novel drug regimens for US Veterans 
with genotype 1 hepatitis C using various strategies to prioritize patients for treatment in light of 
resource constraints. While both drug regimens were cost-effective, we found that treating any 
eligible patient was less costly and more effective than prioritizing treatment of patients with 
advanced disease. Next, we determined the degree to which the current Medicaid policy 
restricting hepatitis C treatment to patients with advanced disease would lead to increased long-
term costs and worse health outcomes for Medicare and the Centers for Medicare and Medicaid 
Services. We found that full access to hepatitis C treatment was cost saving and more effective 
compared to restricting treatment to patients with advanced disease from both perspectives. A 
full access strategy could also avert numerous future liver transplants, cases of hepatocellular 
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carcinoma, and deaths. Finally, we evaluated geographic disparities in surgical intervention for 
hepatocellular carcinoma and determined the influence of physician recommendations on the 
type of treatment a patient ultimately receives. Interestingly, we found that urban patients who 
live closer to high volume centers are less likely to undergo surgical intervention. Furthermore, 
disparities tend to exist in referral for surgical intervention; once referred, most patients receive 
the recommended surgical procedure. These studies reveal opportunities to improve treatment of 
patients with hepatitis C and hepatocellular carcinoma, which could ultimately interrupt the 
continuum of chronic liver disease and improve health outcomes. 
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PREFACE 
 
Research reported in this publication was supported by the National Center For Advancing 
Translational Sciences of the National Institutes of Health under Award Number TL1TR000145. 
The content is solely the responsibility of the authors and does not necessarily represent the 
official views of the National Institutes of Health. The article included in Chapter 4 was 
published in Annals of Surgery and the publisher retains the copyright for this material (1).   
The Pennsylvania Health Care Cost Containment Council (PHC4) is an independent state 
agency responsible for addressing the problem of escalating health costs, ensuring the quality of 
health care, and increasing access to health care for all citizens regardless of ability to pay. PHC4 
has provided data to this entity in an effort to further PHC4’s mission of educating the public and 
containing health care costs in Pennsylvania. PHC4, its agents, and staff, have made no 
representation, guarantee, or warranty, express or implied, that the data – financial, patient, 
payor, and physician specific information – provided to this entity, are error-free, or that the use 
of the data will avoid differences of opinion or interpretation. This analysis was not prepared by 
PHC4. This analysis was done by researchers at the University of Pittsburgh. PHC4, its agents 
and staff, bear no responsibility or liability for the results of the analysis, which are solely the 
opinion of this entity. Similarly, this content does not necessarily represent the official views of 
the VA Healthcare Systems. 
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1.0  INTRODUCTION 
Chronic liver disease is a major cause of morbidity and mortality worldwide (2, 3). In contrast to 
many other forms of disease, chronic liver disease often occurs along a lifelong continuum, 
which presents unique challenges and opportunities for intervention (Figure 1.1). In the United 
States, 3 to 5 million patients are currently infected with hepatitis C virus and develop chronic 
infection, which can be asymptomatic for decades (4, 5). Left untreated, chronic hepatitis C can 
lead to liver cirrhosis, decompensated cirrhosis, and liver transplantation (6-8). Patients with 
cirrhosis are also at an increased risk of developing hepatocellular carcinoma, the most common 
form of primary liver cancer and the second leading cause of cancer death worldwide (9).  
 
 
 
 
Figure 1.1. The Continuum of Chronic Liver Disease 
 2 
There are a number of opportunities to improve treatment and interrupt the continuum of 
chronic liver disease (Figure 1.1). For patients with hepatitis C, successful treatment can reduce 
or eliminate the risk of future complications, but historic regimens have been ineffective and 
poorly tolerated (5). Newly approved interferon-free medication regimens are highly effective, 
but extremely high costs threaten their widespread use (6-8). For patients with hepatocellular 
carcinoma, there has been little progress in improving treatment over the past 40 years, so it is 
essential to maximize the effectiveness and reach of existing treatment options (9). Although 
surgical intervention can be curative for patients with hepatocellular carcinoma, surgical care has 
been inequitably distributed (10-12).  
The projects in this dissertation address each of these issues. In Project 1, we evaluate the 
cost-effectiveness of strategies to treat US Veterans with highly effective but extremely costly 
novel therapeutic regimens for hepatitis C. In Project 2, we estimate the effects of restrictive 
treatment policies on Medicare and government payer costs and health outcomes, and then 
evaluate the cost-effectiveness of expanding access to treatment. Finally, in Project 3, we 
determine whether geographic factors, such as proximity to a surgical center and urban/rural 
residence, are associated with variations in referral for and receipt of surgical intervention for 
hepatocellular carcinoma.  
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2.0  COST-EFFECTIVENESS OF NOVEL TREATMENT STRATEGIES FOR 
HEPATITIS C 
2.1 BACKGROUND  
Hepatitis C (HCV) affects over 174 million people worldwide and up to 5 million people in the 
US (10, 11). Although patients often remain asymptomatic for years, chronic HCV infection is a 
leading cause of liver cirrhosis and hepatocellular carcinoma and the most common indication 
for liver transplantation in the US (6, 7, 12). Patients with HCV experience substantially higher 
mortality than the general population (8, 13, 14). Although there are 6 HCV genotypes, 
approximately 75% of US patients are infected with genotype 1 (15, 16). Successful HCV 
treatment leads to sustained virologic response, improving quality of life and reducing morbidity 
and mortality (8, 17-20). However, due in part to the poor efficacy and eligibility restrictions for 
prior therapeutic options, many HCV patients remain untreated (5, 21-23). 
Recently approved HCV drug regimens have dramatically improved treatment efficacy, 
but high drug prices have necessitated novel strategies for determining which patients would 
benefit most from treatment. Historically, HCV treatment regimens have included pegylated 
interferon, ribavirin and direct acting antiviral drugs (telaprevir or boceprevir). These regimens 
required up to 48 weeks of therapy, were only modestly efficacious, and caused significant dose-
limiting morbidity (24-27). In 2013, the FDA approved two new drugs, sofosbuvir and 
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simeprevir, which improved treatment efficacy to over 90% in many patient subgroups (28-34). 
These regimens still included poorly tolerated interferon for most patients and cost up to $1800 
per dose. With these high treatment costs, two studies evaluating restricting treatment to patients 
with advanced liver disease concluded that treating all patients was more cost-effective (30, 35). 
One of these studies found that it was cost-effective to prioritize those with advanced disease in 
select patient subgroups (35). Since these analyses, a new wave of interferon-free regimens 
received FDA approval, including sofosbuvir/ledipasvir (SOF/LDV) and a multidrug regimen of 
ombitasvir, ritonavir, paritaprevir and dasabuvir (3D), with or without ribavirin. Both of these 
regimens result in nearly universal cure rates with lower costs than sofosbuvir/simeprevir and 
without the adverse effects or eligibility restrictions of interferon-based regimens. 3D is more 
effective and less expensive per dose than SOF/LDV, but requires multiple daily pills for 12-24 
weeks, compared to 8-12 weeks of a single daily dose of SOF/LDV (36-40). In addition, 3D 
includes ritonavir, which has drug interactions precluding its use in some patients, and may 
require ribavirin, which can cause dose-limiting anemia (37, 38, 41). Both regimens are more 
costly than sofosbuvir/ribavirin/interferon, with wholesale prices of up to $1125 per dose. 
The Veterans Health Administration (VA) is a leading provider of HCV care in the US 
and a useful model for evaluating changes in treatment policy. HCV prevalence is two-fold 
greater in Veterans than the general US population with more than 170,000 HCV positive 
Veterans currently receiving VA healthcare (42, 43). VA’s unified national electronic medical 
record system and its national Hepatitis C Clinical Case Registry provide extensive data about 
the natural history of hepatitis C and associated treatment costs, distinguishing VA as an 
excellent system in which to model changes in treatment policy (22).  
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With the advent of interferon-free therapy, optimal treatment for genotype 1 HCV 
remains unclear. Because of differences in drug pricing, treatment duration, efficacy, and quality 
of life associated with SOF/LDV and 3D, it is unclear which drug regimen is most cost-effective. 
Because newer regimens are so costly, it is important to determine how they compare to 
previously used sofosbuvir regimens and to assess whether alternative strategies, such as 
prioritizing patients with advanced disease, may now be cost-effective. Thus, we compared the 
cost-effectiveness of managing a cohort of treatment-naïve genotype 1 HCV patients using 
SOF/LDV versus 3D, and sought to determine whether certain patients should be prioritized for 
treatment. 
2.2 METHODS 
2.2.1 Model Structure and Perspective 
We created a Markov state-transition model with one-year cycle length to compare the cost-
effectiveness of treatment strategies for a cohort of previously untreated, 60-year-old US 
Veterans with genotype 1 HCV mono-infection. The cohort did not include patients with 
decompensated cirrhosis or HIV co-infection at baseline. We used a lifetime time horizon and 
took a VA perspective, including drug and medical costs. We conducted sensitivity analyses 
including relative prices (i.e., differences in cost between regimens) for each treatment regimen 
to make our results generalizable to systems with alternative price structures. Future costs and 
utilities were discounted 3% per year (44). Costs were adjusted to 2014 US dollars using the 
Consumer Price Index.  
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2.2.2 Model Cohort 
We examined a hypothetical cohort of untreated HCV patients seeking treatment in VA in a 
given year, with an average age and distribution of fibrosis similar to that of VA HCV patients in 
2013 (22). We defined chronic HCV severity using the Meta-analysis of Histologic Data in Viral 
Hepatitis (METAVIR) histologic scoring system: F0, no hepatic fibrosis; F1, portal fibrosis 
without septa; F2, portal fibrosis with few septa; F3, many septa without cirrhosis; F4, cirrhosis 
(45). After treatment, patients could experience sustained virologic response, remain infected and 
progress through stages of fibrosis, develop cirrhosis or hepatocellular carcinoma, undergo liver 
transplantation, or die (Figure 2.1). Age-specific, annual all-cause mortality was estimated using 
US life tables (46). Excess mortality associated with HCV infection was estimated using 
METAVIR stage and treatment status. For Veterans with F0-F2 fibrosis, we assumed that after 
sustained virologic response, annual treatment costs, QALYs, morbidity and mortality would be 
similar to uninfected Veterans. For those with F3 or F4 disease, we assumed that morbidity and 
mortality were significantly reduced after sustained virologic response (Table 2.1). Each year, 
patients accrued the costs and QALYs associated with their current Markov state. Only one state 
transition was possible during each model cycle, and progression occurred according to 
previously established transition probabilities (Table 2.1).  
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Figure 2.1 Markov State Transition Model Simulating the Natural History of Hepatitis C 
Note: Transition probabilities derived from recent population-based studies. F0-2, F3 and F4 represent METAVIR 
stages of hepatic fibrosis. F3 and F4 treated states involve reduced risks of liver-related morbidity and mortality 
compared to untreated states. 
 8 
Table 2.1 Hepatitis C Cohort Characteristics, Natural History, Costs, and Utilities 
Description Base Case Low High Distribution Source 
Cohort Characteristics 
     Age (years) 60 50 70 Gamma VA CCR 
F0-2 (%) 0.76 0.56 0.85 Dirichlet (5, 47) 
F3 (%) 0.12 0.11 0.44 Dirichlet (5, 47) 
Interferon-Ineligible (%) 0.37 0.20 0.57 Beta (48) 
Genotype 1a (%) 0.65 0.50 0.75 Beta (15, 49) 
<6 million HCV RNA 0.59 0.10 0.99 Beta (40) 
Risk of Disease Progression (%) 
    F0-2 to F3 0.12 0.11 0.13 Beta (50) 
F3 to F4 0.12 0.09 0.14 Beta (50) 
F3 to HCC 0.01 0 0.03 Beta (51) 
F4 to DC 0.04 0.01 0.04 Beta (51, 52) 
F4 to HCC 0.03 0.01 0.08 Beta (51, 53) 
DC to HCC 0.07 0.03 0.08 Beta (12) 
DC to Transplant 0.03 0.02 0.06 Beta (47, 54) 
HCC to Transplant 0.04 0 0.14 Beta (55, 56) 
Progression After SVR (%) 
     F3 to HCC 0.007 0.006 0.008 Beta (8) 
F4 to DC 0.005 0.002 0.096 Beta (19) 
F4 to HCC 0.005 0 0.019 Beta (19) 
Mortality Rates      
Hepatitis C* 2.37 1.28 4.38 Lognormal (14) 
Cirrhosis (RR)† 2.50 1.23 5.08 Lognormal (17) 
SVR* 1.00     
SVR after F4 (RR)‡ 0.39 0.14 0.65 Lognormal (8, 17, 18) 
DC (%) 0.10 0.04 0.21 Beta (12) 
HCC (%) 0.43 0.34 0.51 Beta (52) 
Transplant Year 1 (%) 0.14 0.06 0.42 Beta (57, 58) 
Transplant Year 2+ (%) 0.03 0.02 0.11 Beta (58) 
Annual Follow-Up Costs (2014 $US) 
F0-3 $190  $90  $555  Gamma (19) 
F4 $1,264  $740  $1,789  Gamma (19) 
DC  $16,214  $12,971  $40,076  Gamma (19) 
HCC Treatment  $50,754  $26,124  $75,384  Gamma (19) 
Transplant Year 1 $310,023  $248,019 $372,028  Gamma (19) 
Transplant Year 2+ $46,985  $37,588  $56,382  Gamma (19) 
SVR (F0-2) $0      
Note: DC - compensated cirrhosis, F0-2, F3, F4 - METAVIR stages of hepatic fibrosis, G1a - genotype 
1a, HCC - hepatocellular carcinoma, HCV – hepatitis C virus, RR - relative risk, SVR – sustained 
virologic response, VA CCR – VA Clinical Case Registry 2013, * - compared to all-cause mortality, † - 
compared to F0-2, ‡ - compared to pre-treatment state 
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Table 2.1 Hepatitis C Cohort Characteristics, Natural History, Costs and Utilities (Continued) 
Description Base Case Low High Distribution Source 
 
Utilities before SVR      
F0-2 0.85 0.83 0.87 Beta (57, 59) 
F3 0.79 0.77 0.81 Beta (57, 59) 
F4 0.76 0.67 0.79 Beta (57, 59) 
DC 0.69 0.44 0.69 Beta (19) 
HCC 0.67 0.6 0.72 Beta (19) 
Transplant Year 1 0.5 0.3 0.8 Beta (19) 
Transplant Year 2+ 0.77 0.57 0.77 Beta (19) 
Utilities After SVR 
    
 
F0-2 0.92 0.9 0.94 Beta (19) 
F3 0.86 0.84 0.88 Beta (19) 
F4 0.83 0.81 0.85 Beta (19) 
Note: DC - compensated cirrhosis, F0-2, F3, F4 - METAVIR stages of hepatic fibrosis, G1a - genotype 
1a, HCC - hepatocellular carcinoma, HCV – hepatitis C virus, RR - relative risk, SVR – sustained 
virologic response, VA CCR – VA Clinical Case Registry 2013, * - compared to all-cause mortality, † - 
compared to F0-2, ‡ - compared to pre-treatment state 
 
 
 
2.2.3 Model Assumptions 
To model HCV natural history, we made a number of assumptions. The METAVIR score has 
been used more widely in the literature than the FIB-4 scoring system used in VA. Because FIB-
4 scores of 3.25 or above correlate with biopsy results demonstrating advanced liver disease, we 
estimated that 50% of patients with FIB-4 scores above 3.25 had METAVIR F3 disease, while 
the others had METAVIR F4 disease (60). We also assumed that liver transplantation would not 
occur after age 75 (61). Finally, we assumed no additional costs for HCV sub-genotyping 
because this is routinely performed for HCV patients in the VA. 
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2.2.4 Costs and Effectiveness 
We obtained VA drug costs from VA Pharmacy Benefits Management and varied them by ±25% 
in sensitivity analyses. Because VA prices for SOF/LDV and 3D were not determined at the time 
of the study and are not publicly available, we assumed that both drugs were discounted at the 
Federal Supply Schedule price, reflecting the 24% minimum discount from average wholesale 
prices required for federal contracts. We varied the absolute and relative prices of these regimens 
in sensitivity analyses. We also estimated medical monitoring costs based on estimates from 
recent literature reviews (19, 30). These costs included a single pre-treatment office visit, 
complete blood count, complete metabolic panel, and viral load measurement; monthly office 
visits and metabolic panels during treatment; quarterly on-treatment viral load measurements; 
and a post-treatment office visit, viral load measurement, and metabolic panel.  
Treatment regimen efficacy data were obtained from recent clinical trials (Table 2.2). 
Because treatment duration with SOF/LDV for non-cirrhotic patients depends on the viral load at 
treatment initiation, we assumed that the proportion of patients eligible for 8-week therapy was 
similar to that found in the ION-3 study (40, 62). Because some clinicians are using 12 weeks of 
3D for genotype 1a cirrhotic patients, we included this regimen in sensitivity analyses. The 
utility of each treatment regimen was estimated based on patient reports of treatment-related 
quality-of-life from sofosbuvir clinical trials (32, 33, 63). In the base case, we assumed that the 
utility of using SOF/LDV or 3D was similar to that of sofosbuvir/simeprevir, while 3D/ribavirin 
was similar to that of sofosbuvir/ribavirin. 
 
 
 
 11 
Table 2.2 Hepatitis C Treatment Parameters 
Parameters Base Case Low High Distribution Source 
Treatment Efficacy      
Sofosbuvir/Interferon/RBV 0.92 0.80 0.99 Beta (28, 64) 
Sofosbuvir/Interferon/RBV (F4) 0.80 0.66 0.89 Beta (28) 
Sofosbuvir/Simeprevir 0.95 0.79 1.00 Beta (29) 
Sofosbuvir/Simeprevir (F4) 0.94 0.73 1.00 Beta (29) 
SOF/LDV (8 weeks) 0.94 0.90 0.97 Beta (40) 
SOF/LDV (12 weeks) 0.96 0.92 1.00 Beta (39, 40) 
SOF/LDV (F4) 0.97 0.84 1.00 Beta (39) 
3D/RBV Genotype 1a 0.96 0.93 0.98 Beta (36, 37) 
3D/RBV Genotype 1a (F4) 0.94 0.90 0.98 Beta (38) 
3D Genotype 1b 0.99 0.98 1.00 Beta (37) 
3D/RBV Genotype 1b (F4) 0.99 0.96 1.00 Beta (38) 
Treatment Disutilities      
Sofosbuvir/RBV -0.04 -0.05 -0.03 Beta (32, 33) 
Sofosbuvir/Interferon/RBV -0.11 -0.12 -0.09 Beta (32, 33) 
Sofosbuvir/Simeprevir 0 -0.04 0 Beta (57) 
Drug Costs (weekly, ±25%)      
Interferon $178 $134 $223 Gamma VA PBM 
Ribavirin $42 $32 $53 Gamma VA PBM 
Simeprevir $2,641 $1,981 $3,301 Gamma VA PBM 
Sofosbuvir $3,796 $2,847 $4,745 Gamma VA PBM 
SOF/LDV $5,985 $4,489 $7,481 Gamma Estimated 
3D $5,277 $3,958 $6,596 Gamma Estimated 
Medical Monitoring Costs (each, ±25%)     
Office visits $76.19 $57.14 $95.24 Gamma (19, 30) 
Complete blood count $10.32 $7.74 $12.90 Gamma (19, 30) 
Complete metabolic panel $15.27 $11.45 $19.09 Gamma (19, 30) 
Quantitative HCV PCR $61.89 $46.42 $77.36 Gamma (19, 30) 
Note: HCV – hepatitis C, 3D – ombitasvir, ritonavir, paritaprevir, dasabuvir, PCR – polymerase chain 
reaction test, SOF/LDV – sofosbuvir/ledipasvir, VA PBM - VA Pharmacy Benefits Management 
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2.2.5 Treatment Strategies 
We compared seven treatment strategies for both SOF/LDV and 3D (Figure 2.2). Five compared 
using SOF/LDV or 3D to treat: (1) any patient seeking treatment, (2) only patients with cirrhosis, 
(3) only patients with F3-F4 disease, (4) patients with cirrhosis first and then patients with F0-3 
disease the following year, or (5) patients with F3-4 disease in the first year, and those with F0-2 
disease one year later. In addition to a no treatment strategy, we also included the previous 
recommendation of the American Association for the Study of Liver Diseases to use 
sofosbuvir/interferon/ribavirin for all eligible patients and sofosbuvir/simeprevir for interferon-
ineligible patients. Treating only F0-2 patients was considered ethically unjustifiable and was not 
included in the analysis. 
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Figure 2.2 Decision Tree with Strategies for Managing Hepatitis C in US Veterans 
Note: 3D - ombitasvir, ritonavir, paritaprevir, dasabuvir ± ribavirin, F0-F4 – METAVIR stages of hepatic fibrosis, 
Previous SOC - sofosbuvir/pegylated interferon/ribavirin or sofosbuvir/simeprevir as appropriate, SOF/LDV – 
sofosbuvir/ledipasvir. 
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2.2.6 Analyses 
In our base case analysis, we calculated the incremental cost-effectiveness ratio (ICER), the 
additional cost required to derive additional QALYs for a given treatment strategy compared to a 
less costly and less effective strategy. Strategies that were more costly and less effective or had 
higher ICERs than more effective strategies were considered dominated (65). Although the VA 
does not use cost-effectiveness thresholds to make treatment decisions, $100,000 per QALY is 
often considered a reasonable threshold for cost-effectiveness in contemporary studies (66, 67). 
We conducted one-way sensitivity analyses to determine whether varying any single model input 
changed the preferred strategy and included estimates for the general population in all ranges. 
Finally, we conducted Monte Carlo probabilistic sensitivity analyses in which all model inputs 
were simultaneously varied. Values were sampled from each variable’s probability distribution 
over 5,000 iterations to determine the likelihood that a given strategy would be cost-effective 
(68). Distributions were chosen based on parameter characteristics: beta distributions were used 
for transition probabilities, treatment efficacy, annual mortality rates, utilities, and cohort 
characteristics; gamma distributions were used for model costs; Dirichlet distributions were used 
for fibrosis staging; and log-normal distributions were used for relative risks of mortality (Table 
2.1, Table 2.2). Analyses were performed using TreeAge Pro 2014 (TreeAge Software, Inc., 
Williamstown, MA). 
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2.3 RESULTS 
2.3.1 Validation 
We validated the model using the no treatment strategy ($38,246, 9.0 QALYs). Our results are 
similar to those in recent cost-effectiveness analyses (69, 70). To further validate the model, we 
created survival and state probability curves for the no treatment strategy, which were compared 
to recent estimates of the changing natural history of HCV (5). Our estimates of the magnitude 
and timing of the peak annual prevalence for decompensated cirrhosis, hepatocellular carcinoma, 
and overall survival were similar to reported values (±15% relative to previous estimates).  
2.3.2 Base Case Analysis 
Compared to no treatment, we found that treating any patient with SOF/LDV cost an additional 
$29,436 and yielded an additional 4.88 QALYs (or $6,027/QALY gained). Treating any patient 
with 3D cost an additional $8,683 and yielded 0.04 additional QALYs compared to SOF/LDV 
($197,782/QALY). Strategies treating only patients with F3 fibrosis and/or cirrhosis and those 
treating patients with F3 fibrosis or cirrhosis first were dominated (Table 2.3). The previous 
standard of care, sofosbuvir with interferon and ribavirin or sofosbuvir with simeprevir, was also 
dominated (Table 2.3). 
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Table 2.3 Cost-Effectiveness of Treating Hepatitis C Among US Veterans: Base Case Results 
Strategy Costs QALYs ICER ($/QALY) 
No Treatment $38,426  9.0  -- 
Treat Any: SOF/LDV $67,682  13.9 $6,027  
Treat Any: 3D $76,365  14.0 $197,782  
Treat When F4: SOF/LDV $51,908  10.5 Dominated 
Treat When F3/F4: SOF/LDV $61,233  12.2 Dominated 
Staged F4 First: SOF/LDV $67,146  13.6 Dominated 
Staged F3/F4 First: SOF/LDV $67,196  13.6 Dominated 
Treat When F4: 3D $67,731  10.5 Dominated 
Treat When F3/F4: 3D $68,573  12.3 Dominated 
Treat Any: Previous SOC $68,620  13.7 Dominated 
Staged F3/4 First: 3D $75,699  13.7 Dominated 
Staged F4 First: 3D $75,980  13.6 Dominated 
Note: F3, F4 – METAVIR stages of fibrosis, ICER – incremental cost-effectiveness ratio, 
3D – ombitasvir, ritonavir, paritaprevir with dasabuvir, Previous SOC – sofosbuvir with 
pegylated interferon/ribavirin or simeprevir, QALY – quality adjusted life-year, 
SOF/LDV – sofosbuvir/ledipasvir 
 
 
 
2.3.3 One-Way Sensitivity Analysis 
In one-way sensitivity analysis, cost-effectiveness ratios were impacted by changes in several 
key variables, including 3D and SOF/LDV efficacy and the relative costs of each drug regimen. 
3D was cost-effective at a $100,000/QALY threshold if <29% of patients were eligible for the 8-
week SOF/LDV regimen, or if SOF/LDV was <92% effective. In addition, SOF/LDV was no 
longer preferred if the 12-week SOF/LDV regimen was <93% effective for non-cirrhotic patients 
or <90% effective for cirrhotic patients, if 3D was >97% effective for patients with genotype 1a 
or if <50% of patients had genotype 1a disease. Finally, when the unit cost of 3D was at least 
18% less than that of SOF/LDV, treating any patient with 3D became cost-effective at 
$100,000/QALY. The ICER was robust to variations in all other model parameters, including 
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cohort age. When we included a 12-week regimen of 3D for genotype 1a cirrhotic patients, 
treating any with 3D became the preferred strategy ($91,720/QALY). 
2.3.4 Probabilistic Sensitivity Analysis 
In our probabilistic sensitivity analysis, treating any patient with SOF/LDV was preferred in 60% 
of iterations at a willingness-to-pay threshold of $50,000/QALY and 58% of iterations at a 
willingness-to-pay threshold of $100,000 per QALY (Figure 2.3). Treating any patient with 3D 
became the most cost-effective treatment option at a willingness-to-pay threshold of 
≥$215,000/QALY gained. 
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Figure 2.3 Probabilistic Sensitivity Analysis of Hepatitis C Treatment Strategies for US Veterans 
Note: F3 and F4 – METAVIR stages of hepatic fibrosis, 3D – ombitasvir, ritonavir, paritaprevir, dasabuvir ± 
ribavirin, Previous SOC – sofosbuvir/pegylated interferon/ribavirin or sofosbuvir/simeprevir as appropriate, 
SOF/LDV – sofosbuvir/ledipasvir. Treating when F3/F4 and Treating F3/F4 first with 3D and SOF/LDV, and 
Treating F4 first with 3D were cost-effective in <5% of iterations and are not depicted.  
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2.4 DISCUSSION 
In this cost-effectiveness analysis, we found that, for a cohort of treatment-naïve genotype 1 
HCV-infected Veterans, managing patients with SOF/LDV regardless of disease status was the 
most economically reasonable strategy. Treating patients with 3D was marginally more effective, 
but considerably more expensive unless the price was substantially reduced relative to 
SOF/LDV. We found it economically unfavorable to restrict treatment to patients with 
METAVIR F3-F4 disease or prioritize treatment of these patients in early years. The cost-
effectiveness of 3D versus SOF/LDV depended on the efficacy and price of each drug regimen 
and the proportion of patients with genotype 1a.  
We demonstrated that regimens using 3D were more costly and more effective than those 
based on SOF/LDV. SOF/LDV was more cost-effective at a threshold of $100,000 per QALY, 
but ICERs of up to $300,000 per QALY have been considered cost-effective in contemporary 
studies (66, 67). Though the unit price of 3D is less than that of SOF/LDV, 3D strategies were 
more costly due to differences in cost and efficacy for patients with genotype 1a disease, who 
comprised 65% of the study population. For example, some patients would be eligible for 8 
weeks of therapy with SOF/LDV, which was less expensive than the 12 weeks required for 
3D/ribavirin, under our assumptions. Similarly, cirrhotic patients may require up to 24 weeks of 
treatment with 3D/ribavirin, which is almost twice as costly as the 12 weeks of SOF/LDV they 
would otherwise receive. Varying the price, efficacy, or duration of these treatments could 
change the preferred strategy, so price negotiations and real-world effectiveness data will inform 
the true cost-effectiveness of each regimen. 
In addition, we found that restricting treatment or prioritizing advanced disease was not 
cost-effective at $100,000/QALY. This was because these strategies had higher ICERs than 
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treating any eligible patient and were eliminated from further consideration based on current 
guidelines (65). This is likely because patients with advanced disease require longer, more costly 
treatment and have a higher risk of morbidity and mortality after sustained virologic response 
than healthier patients (65). These findings are similar to those of previous studies, in which 
staging-guided therapy was not favorable compared to treating all patients (30). In one study, 
staging-guided therapy was cost-effective for patients with cirrhosis, but only when compared to 
waiting one year for treatment with future regimens (35). These results suggest that treating 
healthier patients is more cost-effective than treating sicker ones. However, strategies favoring 
treatment of healthier patients are clinically and ethically unfavorable; treating the sickest 
patients first is ethically ideal. In practice, it is unlikely that all cirrhotic patients can be quickly 
identified and prepared for treatment, so there may be opportunities for healthy patients to be 
treated as well. Thus it may be preferable to implement a triage policy similar to that employed 
in emergency rooms, in which efforts are made to identify and treat the sickest patients, but 
healthier patients are also treated whenever possible. 
We also found that interferon-free treatment regimens were preferred to the previous 
standard of care. This is likely because new interferon-free regimens are more efficacious, have 
improved quality of life compared to interferon-containing regimens, and are less costly than 
sofosbuvir/simeprevir. Our findings are consistent with prior studies, in which interferon-free 
regimens were cost-effective at a $50,000/QALY threshold compared to previous therapeutic 
options (30, 70). 
While we demonstrate that treating any patient is cost-effective compared to restricted 
strategies, practical limitations influence the application of these findings. VA policy allows for 
HCV treatment in all patient populations, however clinical capabilities and financial limitations 
 21 
dictate that it will take several years to treat the hundreds of thousands of VA HCV patients. 
Even without clinical capacity limitations, treating only 70,000 untreated VA HCV patients at a 
discounted price of $50,000 per treatment course would require $3.5 billion in pharmacy costs 
for HCV alone. By comparison, in 2014, HCV treatment accounted for $520 million of the $4.8 
billion in total pharmacy purchasing through the VA Pharmaceutical Prime Vendor (Vincent 
Calabrese, VA Pharmacy Benefits Management, Hines, IL, written communication, 2/10/15). 
Due to limited resources, clinicians will ultimately determine when to treat individual patients. 
Our results have important policy implications for the VA and may be more broadly 
applicable to state Medicaid and national Medicare systems, which assume both the costs and 
benefits of treatment. Though resource constraints clearly limit treatment capabilities, our 
analyses suggest that short-term efforts to improve treatment capacity could ultimately lead to 
significant long-term improvements in health outcomes and reduced costs for patients with HCV. 
To improve throughput, VA is considering a number of potential strategies, including using 
primary care and telehealth providers in uncomplicated cases. Similar strategies could be 
employed by other healthcare systems to improve the public health impact of HCV treatment.  
Our study has some limitations. First, instead of modeling fibrosis regression, we used 
stage-specific progression rates to account for slower disease progression after sustained 
virologic response. Second, we did not stratify our analyses by gender or race/ethnicity because 
neither parameter has been demonstrated to impact sustained virologic response in recent trials. 
Third, our analyses do not consider aggregate cost, clinic availability or differing models of care. 
Fourth, we derived treatment efficacy data from clinical trials, however success rates may be 
lower in real-world clinical practice. Finally, our analyses are conducted from the VA 
perspective, including VA-specific drug pricing. To improve the generalizability of our results, 
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we included general population data in ranges used for sensitivity analyses and used relative drug 
prices, making our results relevant to systems with other price structures.  
In conclusion, we determined that it is economically reasonable to manage treatment 
naïve US Veterans with genotype 1 HCV using novel interferon-free regimens regardless of 
fibrosis status. Still, we demonstrate that treatment efficacy is an important aspect of cost-
effectiveness. In addition to monitoring the real world effectiveness of both drugs, it will become 
important to identify predictors of adherence, sustained virologic response, and reinfection after 
successful treatment. Interferon-free regimens for genotype 1 HCV can confer long-term health 
benefits for US Veterans and are cost-effective regardless of fibrosis status. 
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3.0  ECONOMIC AND PUBLIC HEALTH IMPACTS OF POLICIES RESTRICTING 
ACCESS TO HEPATITIS C TREATMENT FOR MEDICAID PATIENTS 
3.1 BACKGROUND 
Hepatitis C affects over 3.2 million patients in the United States and is a common cause of 
chronic liver disease worldwide (10, 11). Most infected patients develop chronic disease that can 
remain asymptomatic for decades. However, left untreated, chronic hepatitis causes progressive 
hepatic fibrosis, which can result in severe complications. After developing cirrhosis, patients are 
at risk for hepatocellular carcinoma, may require liver transplantation, and have a markedly 
increased risk of early mortality (6-8). Successful treatment can drastically reduce the morbidity 
associated with chronic hepatitis C infection and improve patients’ quality of life (8, 17, 18).  In 
fact, if recent advances in drug regimens are widely implemented, hepatitis C could become a 
rare disease as early as 2036 (5). 
Whereas new hepatitis C treatments are highly effective and have few side effects, their 
high costs could limit access to these medications. The preceding generation of interferon-based 
treatment regimens were poorly tolerated by patients and required lengthy treatment durations, 
so many patients have remained untreated (21). With the recent introduction of interferon-free 
drug regimens, treatment courses are more than 94% effective in as few as 8 weeks for many 
patient sub-groups, but can cost up to $190,000 per patient (71-73).  
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Resource-constrained government health insurance programs, including Medicaid and 
Medicare, cover a substantial proportion of US patients with hepatitis C and are heavily 
impacted by the high prices of these drugs. In fact, most state Medicaid programs restrict 
treatment of hepatitis C to patients with advanced liver disease, due to medication costs (74). 
Because hepatitis C is most prevalent in patients aged 45 and older, many Medicaid patients with 
early-stage disease may not develop advanced disease or complications until years later, after 
becoming eligible for Medicare (75, 76). 
Though restrictive hepatitis C treatment policies are likely to reduce short-term costs to 
state Medicaid programs, it remains unclear to what degree they shift the financial burden of 
hepatitis C treatment and follow-up to the Medicare program and/or increase overall costs to the 
Centers for Medicare and Medicaid Services (CMS). In addition, the public health impact of 
delaying treatment for early-stage patients until disease progression occurs remains unknown.  
Thus, the aim of this study was to evaluate the cost-effectiveness of current Medicaid policies 
restricting hepatitis C treatment to patients with advanced disease compared to a strategy that 
provides unrestricted access to hepatitis C treatment. Our analyses also assess the budget and 
public health impact of each strategy to estimate the feasibility and long-term effects of 
increasing access to treatment for patients with hepatitis C. 
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3.2 METHODS 
3.2.1 Model Structure and Perspective 
We created a Markov state-transition model to simulate the epidemiology and natural history of 
hepatitis C infection. We conducted cost-effectiveness, budget and public health impact analyses 
from the perspectives of: (1) CMS, which incorporated costs and effects accrued during the 
entire study period; and (2) the Medicare program, which included costs and effects accrued after 
patients became eligible for Medicare benefits. We considered lifetime costs and outcomes, 
adjusted all prices to 2015 US dollars using the Consumer Price Index, and discounted all future 
costs and utilities by 3% per year. The discount rate is used in cost-benefit analyses to reflect the 
lower value placed on future outcomes compared to current outcomes. Empirical evidence 
suggests that an annual discount rate of 3% may account for true time preferences for costs and 
health outcomes, especially from a governmental perspective (44). We varied the discount rate 
from 0-7% in sensitivity analyses.  
3.2.2 Model Cohort 
We modeled hypothetical cohorts of 45-, 50-, and 55-year-old Medicaid patients diagnosed with 
genotype 1 hepatitis C who had no prior history of treatment with interferon-based regimens 
(treatment-naïve) or who had failed therapy with previous regimens (treatment-experienced). 
Based on data from the 2011-2012 National Health and Nutrition Examination Survey 
(NHANES), the average Medicaid patient with hepatitis C is 51 years old, so our selected age 
groups comprise approximately 95% of Medicaid patients with hepatitis C (77). Our cohorts 
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excluded patients with any prior history of decompensated cirrhosis, liver transplantation, or HIV 
co-infection. Chronic hepatitis C disease severity is measured using the Meta-analysis of 
Histologic Data in Viral Hepatitis (METAVIR) score, which describes five stages of liver 
fibrosis: F0, no hepatic fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis with few 
septa; F3, many septa without cirrhosis; F4, cirrhosis (45). In this analysis, we estimated the 
baseline distribution of METAVIR scores using model-based predictions of the HCV-infected 
population in 2014 (Table 3.1) (5, 78). 
3.2.3 Natural History Model 
We created a Markov model to simulate the natural history of hepatitis C infection (Figure 3.1). 
Patients accrued liver-related treatment and follow-up costs as well as quality-adjusted life years 
(QALYs) for their Markov state at the end of each one-year cycle. Patients could make one state 
transition each year. Mortality was possible during each model stage; we estimated age-specific, 
annual all-cause mortality rates using US life tables (46). Disease progression and excess liver-
related mortality occurred according to stage-specific transition probabilities and relative risks of 
mortality established in previously published studies (Table 3.1). 
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Table 3.1 Hepatitis C Cohort Characteristics, Natural History, Costs and Utilities 
Description Base Case Low High Distribution Source 
Cohort Characteristics (%) 
F0-2 0.51 0.38 0.64 Dirichlet (5, 78) 
F3 0.21 0.16 0.26 Dirichlet (5, 78) 
F4 0.28 0.21 0.35 Dirichlet (5, 78) 
Treatment-Naive 0.61 0.46 0.76 Beta (5, 78) 
Risk of Disease Progression (%) 
F0-2 to F3 0.12 0.11 0.13 Beta (50) 
F3 to F4 0.12 0.09 0.14 Beta (50) 
F3 to HCC 0.01 0 0.03 Beta (51) 
F4 to DC 0.04 0.01 0.04 Beta (51, 52) 
F4 to HCC 0.03 0.01 0.08 Beta (51, 53) 
DC to HCC 0.07 0.03 0.08 Beta (12) 
DC to Transplant 0.03 0.02 0.06 Beta (47, 54) 
HCC to Transplant 0.04 0 0.14 Beta (55, 56) 
Progression After SVR (%)      F3 to HCC 0.007 0.006 0.008 Beta (8) 
F4 to DC 0.005 0.002 0.096 Beta (19) 
F4 to HCC 0.005 0 0.019 Beta (19) 
Mortality Rates 
Hepatitis C* 2.37 1.28 4.38 Lognormal (14) 
Cirrhosis (RR)† 2.50 1.23 5.08 Lognormal (17) 
SVR* 1.00 -- -- -- Estimate 
SVR after F4 (RR)‡ 0.39 0.14 0.65 Lognormal (8, 17, 18) 
DC (%) 0.10 0.04 0.21 Beta (12) 
HCC (%) 0.43 0.34 0.51 Beta (52, 79) 
Transplant Year 1 (%) 0.14 0.06 0.42 Beta (57, 58) 
Transplant Year 2+ (%) 0.03 0.02 0.11 Beta (58) 
Annual Follow-Up Costs (2015 $US) 
F0-3 1,357 89 4,072 Gamma (19, 30, 80) 
F4 1,409 729 3,342 Gamma (19, 30, 80) 
DC  22,338 12,768 39,446 Gamma (19, 80) 
HCC 47,885 25,713 74,200 Gamma (19, 80) 
Transplant Year 1 228,090 165,537 366,183 Gamma (19, 80, 81) 
Transplant Year 2+ 38,662 36,998 55,497 Gamma (19, 80) 
SVR (F0-2) 0 -- -- -- Estimate 
Note: DC - decompensated cirrhosis, F0-2, F3, F4 - METAVIR stages of hepatic fibrosis, HCC - 
hepatocellular carcinoma, RR - relative risk, SVR - sustained virologic response, * - compared to 
all-cause mortality, † - compared to F0-2, ‡ - compared to pre-treatment state. 
28 
Table 3.1 Hepatitis C Cohort Characteristics, Natural History, Costs and Utilities (Continued) 
Description Base Case Low High Distribution Source 
Utilities before SVR 
F0-2 0.85 0.83 0.87 Beta (57, 59) 
F3 0.79 0.77 0.81 Beta (57, 59) 
F4 0.76 0.67 0.79 Beta (57, 59) 
DC 0.69 0.44 0.69 Beta (19) 
HCC 0.67 0.6 0.72 Beta (19) 
Transplant Year 1 0.50 0.30 0.80 Beta (19) 
Transplant Year 2+ 0.77 0.57 0.77 Beta (19) 
Utilities After SVR 
F0-2 0.92 0.90 0.94 Beta (19) 
F3 0.86 0.84 0.88 Beta (19) 
F4 0.83 0.81 0.85 Beta (19) 
Note: DC - decompensated cirrhosis, F0-2, F3, F4 - METAVIR stages of hepatic fibrosis, HCC - 
hepatocellular carcinoma, RR - relative risk, SVR - sustained virologic response, * - compared to 
all-cause mortality, † - compared to F0-2, ‡ - compared to pre-treatment state. 
Figure 3.1 Markov State Transition Model Simulating the Natural History of Hepatitis C 
Note: Transition probabilities derived from recent population-based studies. F0-2, F3 and F4 represent METAVIR 
stages of hepatic fibrosis. F3 and F4 treated states involve reduced risks of liver-related morbidity and mortality 
compared to untreated states.  
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At baseline, we grouped patients into three stages of baseline disease severity: early-stage 
disease (METAVIR F0-F2), advanced fibrosis (METAVIR F3), and compensated cirrhosis 
(METAVIR F4). Patients with compensated cirrhosis could later develop complications 
including decompensated cirrhosis, liver transplantation, and hepatocellular carcinoma. Patients 
with early-stage disease, advanced fibrosis, or compensated cirrhosis could receive hepatitis C 
treatment. We assumed that after successful treatment, patients with F0-F2 disease would return 
to full health and accrue no further hepatitis C infection-related costs. In contrast, patients with 
advanced fibrosis or cirrhosis would have markedly reduced risks of disease progression, 
complications, and mortality, but no reduction in follow-up costs after successful treatment 
(Table 3.1).  
3.2.4 Treatment 
We assumed that all patients would be treated with one of two currently available interferon-free 
hepatitis C drug regimens: a single dose two-drug combination of sofosbuvir/ledipasvir 
(SOF/LDV) or a multi-dose three-drug combination of ombitasvir, paritaprevir, and ritonavir 
with dasabuvir (3D). The American Association for the Study of Liver Diseases currently 
recommends both of these treatments for patients with genotype 1 hepatitis C (Table 3.2). 
Because utility data were not available for the 3D regimen at the time of our analysis, we 
performed our primary analysis using data for SOF/LDV (Table 3.3) and used estimates for 3D 
in sensitivity analyses. We estimated the efficacy of each treatment regimen using data from 
recently published clinical trials (36-40, 82-85). In patient subgroups for which several alternative 
treatment options have demonstrated similar effectiveness, we chose the least costly drug 
regimen. For example, we assumed that treatment-naïve patients with fewer than 6 million 
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copies of hepatitis C viral RNA at baseline would receive treatment with SOF/LDV for 8 weeks 
instead of 12 weeks. Similarly, we assumed that treatment-experienced cirrhotic patients would 
receive 12 weeks of SOF/LDV combined with ribavirin instead of 24 weeks without ribavirin.  
We determined SOF/LDV treatment disutility using data from a quality-of-life study 
conducted as part of a recent clinical trials (86). Because utility data for the 3D and 3D with 
ribavirin regimens were not available, we used treatment disutility data for the SOF/LDV and 
SOF/LDV with ribavirin regimens, respectively, in our sensitivity analysis (Table 3.3). 
 
 
 
Table 3.2 Recommended Treatment Regimens for Genotype 1 Hepatitis C 
 Sofosbuvir/Ledipasvir Three-Drug  
Treatment Naïve   
No Cirrhosis   
 <6 million HCV RNA: 8 weeks, 
>6 million HCV RNA: 12 weeks 
1a: 12 weeks + RBV 
 1b: 12 weeks 
Cirrhosis   
 12 weeks 1a: 24 weeks + RBV  1b: 12 weeks + RBV 
 
Treatment-Experienced 
No Cirrhosis   
Genotype 1a 12 weeks 1a: 12 weeks + RBV Genotype 1b 1b: 12 weeks 
Cirrhosis   
Genotype 1a 24 weeks or 12 weeks + RBV 1a: 24 weeks + RBV Genotype 1b 1b: 12 weeks + RBV 
Note: RBV: ribavirin, Three Drug:  Ombitasvir, paritaprevir/ritonavir plus dasabuvir. 
Source: American Association for the Study of Liver Diseases (hcvguidelines.org), 
Accessed 5/1/2015. 
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Table 3.3 Hepatitis C Treatment Parameters 
Parameters Base Case Low High Distribution Source 
Treatment Efficacy 
SOF/LDV x 8 weeks 0.94 0.90 0.97 Beta (40) 
SOF/LDV x 12 weeks (Naïve) 0.96 0.92 1.00 Beta (39, 40) 
SOF/LDV x 12 weeks (Naïve F4) 0.97 0.84 1.00 Beta (39) 
SOF/LDV x 12 weeks (Experienced) 0.95 0.89 0.99 Beta (82) 
SOF/LDV/RBV x 12 weeks (F4) 0.88 0.72 0.92 Beta (82, 83) 
Treatment Disutilities 
SOF/LDV x 8 weeks 0.03 -0.19 0.25 Normal (86) 
SOF/LDV x 12 weeks 0.04 -0.20 0.28 Normal (86) 
SOF/LDV/RBV x 12 weeks -0.02 -0.30 0.26 Normal (86) 
Drug Costs (weekly) 
 SOF/LDV $5,874 $2,500 $7,875 Gamma NADAC 
Ribavirin $152.78 $114.59 $190.98 Gamma (19) 
Medical Monitoring Costs (each, ±25%) 
Office visits (CPT 99213) $72.94 51.13 $79.69 Gamma MPFS 
Complete blood count $10.58 $8.81 $14.30 Gamma MPFS 
Complete metabolic panel $14.37 $11.51 $19.43 Gamma MPFS 
Quantitative HCV PCR $58.29 $38.61 $78.77 Gamma MPFS 
Note: AWP – Average wholesale price, HCV – hepatitis C, 3D – ombitasvir, ritonavir, and paritaprevir 
with dasabuvir, MPFS – Medicare Physician Fee Schedule 2015, NADAC – National Average Drug 
Acquisition Cost, PCR – polymerase chain reaction test, SOF/LDV – sofosbuvir/ledipasvir 
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3.2.5 Costs and Effectiveness 
We used a variety of sources to estimate treatment and follow-up costs for patients with hepatitis 
C (Table 3.1). In the base case, we discounted the national average drug acquisition price for 
each drug regimen by 23.1%, which is required as part of the Medicaid drug rebate program. 
Although the discount rate accounted for likely reductions in future hepatitis C drug prices, we 
also varied drug prices in sensitivity analysis. We used the Medicare physician fee schedule to 
calculate the costs of on-treatment medical monitoring (87). Expected costs included a single 
pre-treatment office visit, complete blood count, complete metabolic panel, and viral load 
measurement; monthly office visits, viral load measurements and metabolic panels during 
treatment; and a single post-treatment office visit, viral load measurement, and metabolic panel. 
We assumed that patients using ribavirin-containing regimens were monitored more frequently, 
with twice-monthly office visits and complete blood counts (Table 3.3).  
From the Medicare perspective, costs and QALYs began to accrue upon Medicare 
eligibility at age 65. From the CMS perspective, costs and QALYs accrued throughout the study 
period. Because Medicare Part D can involve substantial cost-sharing for seniors not receiving 
Medicaid benefits, we subtracted expected patient out-of-pocket costs estimated using current 
Part D coverage rules (88). Because the prescription drug coverage gap (i.e. “donut hole”) is 
scheduled to be eliminated in 2020, we assumed that this would not be in place by the time the 
oldest cohort becomes eligible for Medicare benefits. 
We determined annual follow-up costs for each health state using recent estimates for 
cohorts of Medicare and managed care patients (19, 30, 80, 81), and used age-specific median 
utility values for healthy patients (89). We estimated utility weights for each hepatitis C-related 
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health state based on recent comprehensive reviews of the literature (19, 57, 59). Finally, we 
varied all parameters over feasible ranges in sensitivity analyses (Table 3.1). 
3.2.6 Strategies 
We compared two strategies for managing hepatitis C infection in cohorts of current Medicaid 
beneficiaries: (1) Current Practice – only patients with advanced fibrosis or cirrhosis are treated 
for hepatitis C before becoming eligible for Medicare, treatment for patients with early-stage 
disease is deferred until disease progression or Medicare eligibility; and (2) Full Access –
patients with early-stage disease, advanced fibrosis, and cirrhosis are treated before becoming 
eligible for Medicare benefits (Figure 3.2).  Because some Medicare Advantage plans are 
adopting more restrictive treatment strategies, we assumed in the base case that 50% of patients 
with early stage disease would be treated upon Medicare eligibility and varied this assumption 
from 0-100% in sensitivity analysis.  
Figure 3.2 Decision Tree with Strategies for Treating Hepatitis C in Medicaid Beneficiaries 
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3.2.7 Assumptions 
To perform this analysis, we made a number of simplifying assumptions to systematically bias 
the model against the “Full Access” strategy. We assumed that: (1) patients who failed treatment 
with sofosbuvir- or ombitasvir-based regimens would not be retreated because guidelines have 
not yet been developed for retreatment after treatment failure with novel regimens; (2) only 
patients 75 years of age or younger would undergo liver transplantation (61); (3) the costs of 
follow-up and treatment would be similar for the Medicaid and Medicare programs; (4) patients 
would become eligible for full Medicare benefits at age 65, however to accounted for Medicare-
Medicaid dual eligibility, we estimated that 14% of Medicaid recipients under age 65 would 
receive Medicare disability benefits while 14% of Medicare beneficiaries over 65 received 
Medicaid benefits (90, 91); and (5) the size of the Medicaid hepatitis C population would remain 
static over time. We accounted for increased prevalence of hepatitis C in the Medicaid 
population in a sensitivity analysis.  
3.2.8 Cost-Effectiveness Analyses 
We completed the analysis separately for cohorts of 45-, 50-, 55-year-old Medicaid beneficiaries 
with hepatitis C. In the base-case analyses, we calculated the incremental cost-effectiveness ratio 
(ICER), which reflects the additional investment required to gain an additional QALY. In recent 
studies, ICER thresholds of $50,000-$300,000/QALY have been considered cost-effective (66, 
67).  
We also conducted sensitivity analyses to determine whether variations in model inputs 
would change the preferred strategy. First, we varied model inputs individually over a range of 
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plausible values in one-way sensitivity analyses (Table 3.1). Then, we used Monte Carlo 
probabilistic sensitivity analyses, in which values are randomly sampled from each variable’s 
probability distribution and repeated over 5,000 iterations to determine the likelihood that each 
strategy is cost-effective (68). We performed all analyses using TreeAge Pro 2015 (TreeAge 
Software, Williamstown, MA). 
3.2.9 Structural Sensitivity Analyses 
Because it is not feasible to treat all Medicaid patients with HCV in a single year, we also 
conducted structural sensitivity analyses using staged treatment strategies, in which patients 
would be treated over time. Using data from the 2011-2012 NHANES survey and recently 
published studies, we estimated that approximately 450,000 patients with genotype 1 hepatitis C 
are currently receiving Medicaid benefits (75, 77, 92). Because the Affordable Care Act 
expanded Medicaid eligibility in many states, more low-income patients will have access to 
Medicaid insurance, some of whom may have chronic hepatitis C. The prevalence of hepatitis C 
in this population is unknown, but in a sensitivity analysis we determined the effects of a 33% 
increase in the size of the Medicaid hepatitis C population. This is likely to be an overestimation 
based on expected enrollment if Medicaid expansion is adopted in all 50 states (93, 94). 
We also estimated treatment capacity for each strategy. Based on total Medicaid hepatitis 
C drug expenditures in 2014 and previous reports of treatment capacity, we estimated that 
approximately 30,000 Medicaid patients with hepatitis C could be treated in a given year (95, 
96). Because more patients are likely to be treated each year under the Full Access strategy, we 
also modeled an expanded Full Access strategy with an annual treatment capacity of 40,000 
patients. Recent developments suggest that increased treatment capacity is likely to be feasible 
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because new drug regimens are now 24-36 weeks shorter in duration than interferon-based 
regimens, allowing more patients to be treated by the same number of physicians in any given 
year. In addition, a recent study demonstrated that primary care providers can effectively 
administer hepatitis C treatment in uncomplicated cases (97). If this practice is widely adopted in 
the U.S., then a much larger physician workforce would be available to treat early-stage patients 
with hepatitis C. To derive approximate annual treatment probabilities, we estimated that 13% of 
early-stage patients die or progress each year, while the number of patients with advanced-stage 
disease is reduced by approximately 1% each year, accounting for entry, progression, and death, 
based on data from our natural history model (Table 3.4). In the Current Practice strategy, 
treatment would be offered to early-stage patients only after all patients with advanced fibrosis or 
cirrhosis have been treated. In the Full Access strategies, treatment would be equally allocated 
across fibrosis stages each year. 
3.2.10 Budget & Public Health Impact Analyses 
Finally, we compared the budget and public health impact of each treatment strategy. We used a 
Markov cohort analysis, which describes the costs and utilities associated with each Markov state 
during each model year. Using these data, it is possible to estimate and compare cost estimates as 
well as adverse health outcomes for each strategy. We first compared the annual and cumulative 
costs for both treatment strategies in our base case analysis. Next, we used the model to estimate 
the annual and cumulative number of cases of adverse health outcomes such as hepatocellular 
carcinoma, liver transplantation, and mortality, per hundred thousand Medicaid recipients. 
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Table 3.4 Annual Treatment Probabilities for Staged Hepatitis C Treatment Strategies 
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3.3 RESULTS 
3.3.1 Base Case Analyses 
In the base case, the Full Access strategy was cost saving compared to the Current Practice 
strategy for all age cohorts from the Medicare perspective (Table 3.5). For the 50-year-old 
cohort, which represented the average Medicaid patient with hepatitis C, the Current Practice 
strategy ($30,306, 5.51 QALYs) cost an additional $9,199 per patient and yielded 0.85 fewer 
QALYs compared to the Full Access strategy ($21,107, 6.36 QALYs). Cost savings for the Full 
Access strategy increased with cohort age.  
From the CMS perspective, the Full Access strategy was also cost saving for each age 
cohort, but to a lesser degree. Compared to the Full Access strategy ($89,825, 15.85 QALYs), 
the Current Practice strategy cost an additional $8,148 per patient and yielded 2.74 fewer 
QALYs ($97,829, 13.11 QALYS) for the 50-year-old cohort (Table 3.5). The Full Access 
strategy was more cost saving for younger cohorts from the CMS perspective.  
3.3.2 Sensitivity Analyses 
In one-way sensitivity analyses from the Medicare perspective, the Full Access strategy was cost 
saving for all age cohorts regardless of variations in any individual model input. From the CMS 
perspective, variations in the cost of follow-up for patients with early-stage disease and in the 
discount rate impacted the ICER differently in each age cohort. The Full Access strategy 
remained cost saving as long as the cost of follow-up for early-stage patients was more than 
approximately $200 per year in the 45-year-old cohort, $350 per year in the 50-year-old cohort, 
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and $600 per year in the 55-year-old cohort. In addition, the Full Access strategy was cost saving 
for discount rates below 5-6%, depending on the age of the cohort. The Full Access strategy was 
cost saving over the range of plausible values for all other model inputs.  
Table 3.5 Cost-Effectiveness of Restricted Access to Hepatitis C Treatment: Base Case Results 
Strategy 
Medicare Perspective CMS Perspective 
Costs QALYs ICER ($/QALY) Costs QALYs 
ICER 
($/QALY) 
45-year-old cohort
Full Access $19,947 5.36 $92,411 17.20 
Current Practice $27,458 4.54 Dominated $102,686 14.19 Dominated 
50-year-old cohort
Full Access $21,107 6.36 $89,825 15.85 
Current Practice $30,306 5.51 Dominated $97,829 13.11 Dominated 
55-year-old cohort
Full Access $22,404 7.61 $86,900 14.40 
Current Practice $34,363 6.80 Dominated $92,268 12.09 Dominated 
Note: ICER - incremental cost-effectiveness ratio, QALY - quality-adjusted life-year 
In probabilistic sensitivity analysis, the Full Access strategy was cost-effective in 100% 
of iterations from the Medicare perspective at all willingness-to-pay thresholds. From the CMS 
perspective, the Full Access strategy was cost-effective in 93% of iterations at the cost saving 
threshold of $0/QALY and in 100% of iterations at $4,500/QALY. Including 3D regimens 
instead of SOF/LDV did not change the preferred strategy from either perspective. In our 
structural sensitivity analysis, the staged Full Access strategy was cost saving compared to the 
staged Current Practice strategy for all age cohorts, regardless of annual treatment capacity or the 
size of the Medicaid hepatitis C population (Table 3.6).  
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Table 3.6 Cost-Effectiveness of Staged Treatment Strategies for Medicaid Patients with Hepatitis C 
  450,000 Patients 600,000 Patients 
Strategy Costs QALYs Costs QALYs 
45-year-old cohort 
    Expanded Full Access $96,453 14.79 $96,800 14.26 
Full Access $96,800 14.26 $96,915 13.68 
Current Practice $99,881 14.14 $100,111 13.60 
50-year-old cohort 
    Full Access $92,067 13.02 $91,672 12.48 
Expanded Full Access $92,156 13.52 $92,067 13.02 
Current Practice $95,196 12.90 $94,949 12.40 
55-year-old cohort 
    Full Access $86,339 11.71 $85,087 11.21 
Expanded Full Access $87,241 12.18 $86,339 11.71 
Current Practice $89,757 11.60 $88,626 11.13 
Note: Current Practice & Full Access – 30,000 patients treated per year, Expanded Full 
Access – 40,00 patients treated per year, QALYs- quality-adjusted life years 
 
 
 
3.3.3 Budget and Public Health Impact Analyses 
Our budget impact analyses revealed that, from the CMS perspective, the Full Access strategy 
became cost saving compared to the Current Practice strategy after 16 years for the 45-year-old 
cohort, after 15 years for the 50-year-old cohort, and after 13 years for the 55-year-old cohort. 
By the end of the study period, the Full Access strategy saved $10,340 per patient for the 45-
year-old cohort, $8,148 for 50-year-olds, and $5,695 for 55-year-old patients. With staged 
treatment strategies, Full Access became cost saving after 9 years for each age cohort. In the 
worst-case scenario, with 600,000 hepatitis C patients and 30,000 treated per year, the Full 
Access strategy saved $3,197-$3,568 per patient by the end of the study period, depending on the 
age of the cohort. The public health impact analysis demonstrated that for every 100,000 50-
year-old Medicaid beneficiaries, the Full Access strategy could avert approximately 5,994 cases 
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of hepatocellular carcinoma and 121 liver transplants compared to the Current Practice strategy. 
The number of cases averted varied over time for each age cohort (Figure 3.3). 
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Figure 3.3 Annual Public Health Impact of Unrestricted vs. Restricted Access to Hepatitis C Treatment 
Among Medicaid Beneficiaries 
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3.4 DISCUSSION 
This cost-effectiveness analysis revealed that for current Medicaid beneficiaries, full access to 
hepatitis C treatment is cost saving compared to the current practice of restricting treatment to 
only patients with advanced liver disease. The increased short-term costs of increasing access to 
care can be recouped in savings from reduced complications in 9-16 years, depending on the 
treatment strategy and age of the cohort. Furthermore, increased access to treatment could avert 
numerous future cases of hepatocellular carcinoma, reduce the need for liver transplantation and 
prevent early mortality.  
We demonstrated that Full Access to hepatitis C treatment was actually cost saving 
compared to the more restrictive Current Practice strategy in the long run. In fact, under ideal 
circumstances, the total savings could exceed $3.5 billion for the 450,000 Medicaid beneficiaries 
with hepatitis C. There are two likely explanations for this phenomenon. First, open access 
would lead to earlier treatment and substantially reduced annual follow-up costs for patients with 
early-stage disease. This interpretation is supported by the results of our sensitivity analysis, 
which demonstrated that the full access strategy is only cost saving if annual follow-up costs for 
early-stage patients exceed $600, meaning that it is economically advantageous to avert these 
costs. Second, open access to treatment would reduce the number of early-stage patients who 
progress to advanced fibrosis or cirrhosis before being treated. This is important because even 
after successful treatment, patients with advanced disease still have high follow-up costs and a 
small risk of developing costly complications, while successfully treated early-stage patients 
have similar outcomes to their uninfected age-matched peers.  
Our results were robust to variations in most model inputs. In sensitivity analyses, the 
Full Access strategy was no longer cost saving for very high discount rates (≥5%) or very low 
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follow-up costs for early-stage patients (<$600), both of which are unlikely. Cost-effectiveness 
guidelines suggest that a 3% discount rate is likely to be appropriate as the Office of 
Management and Budget recently suggested that a 3.4% nominal 30-year interest rate should be 
used for cost-effectiveness analyses (65, 98). Similarly, most studies suggest that costs of follow-
up for early-stage patients with hepatitis C are much higher than $600. Recently, the rate of 
hospitalizations for patients with early-stage and advanced hepatitis C has increased, which 
suggests that the costs of managing these patients are likely to be increasing as well (99).  
Because the assumptions made were generally biased against the Full Access strategy, 
our estimates are likely to be conservative. Our structural sensitivity analysis showed that the 
Full Access strategy was still cost saving if the size of the Medicaid population with hepatitis C 
increased by one-third. However, Medicaid expansion is only expected to increase the program’s 
enrollment by approximately 25% and many new enrollees will likely be children (94). 
Furthermore, the Full Access strategy was cost saving even if there was no associated increase in 
treatment capacity. In reality, doubling the pool of eligible patients is likely to increase the 
absolute number of patients seeking treatment, bounded only by physician availability, patients’ 
knowledge of their disease status, and medical eligibility for treatment. Finally, we assumed that 
drug prices would be similar for Medicare and Medicaid. However, many state Medicaid 
programs are negotiating dramatic price discounts for hepatitis C treatment regimens, which 
could reduce the total cost of the Full Access strategy (100). Meanwhile, because the Medicare 
program cannot negotiate drug prices, the costs of waiting to treat patients after Medicare 
eligibility are likely to be higher than our estimates, which were based on Medicaid prices. 
Our results are consistent with those of recent studies evaluating the impact of novel 
interferon-free treatment regimens. Recent reports have demonstrated that novel interferon-free 
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drug regimens are cost-effective for many patient subgroups (78, 101). One study in particular 
demonstrated that the SOF/LDV regimen could be cost saving compared to the previous standard 
of care if treatment was substantially discounted, but did not evaluate the effects of restrictive vs. 
inclusive treatment strategies (101). In addition, the results of our public health impact analysis 
are consistent with findings from Kabiri et al (5), who also demonstrated that increased access to 
hepatitis C treatment could  result in substantial long-term reductions in morbidity and mortality.  
This study addresses the dilemma of determining which patients with hepatitis C should 
be treated first, which has been highlighted in numerous recent editorials (74, 102, 103). Briefly, 
from one perspective, patients with advanced disease should be treated first because they may 
benefit most in the short-term from treatment, as they have the highest immediate risk of 
morbidity and mortality. From a different perspective, it may not be ethical to require patients 
with early-stage disease to develop advanced fibrosis or cirrhosis before offering them access to 
potentially curative treatments, especially because early-stage patients require shorter, less 
expensive drug regimens. Here, we offer empiric evidence to inform this debate and demonstrate 
that, from a government payer perspective, allowing access to treatment for early-stage patients 
may be the less costly and more effective long-term strategy.  
Our analysis is quite interesting in light of current events in public health. For example, 
the US Preventive Services Task Force recently recommended birth cohort screening for 
hepatitis C for adults born between 1945 and 1965 (104). A recent study determined that 
screening is cost-effective, but assumed that patients would be treated after disease was 
identified, albeit with older regimens (105). It is important to determine whether birth cohort 
screening is still cost-effective if diagnosis with hepatitis C is not paired with treatment 
initiation. Moreover, the epidemiology of hepatitis C in the United States is changing. Although 
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the prevalence is highest among patients aged 45 and older, the incidence of hepatitis C has 
recently been rising at an alarming rate among younger injection drug users (106). Although our 
analysis focused on older cohorts, we demonstrate that Full Access is increasingly cost saving 
for younger patients. Because these younger patients will live with the disease for a longer period 
of time, treating them while they have early-stage disease will avoid the high costs of disease 
management and potential complications that would accrue if these patients were treated after 
disease progression. Treating younger patients may also curb the spread of the disease and 
reduce the duration of the epidemic. 
This study has some limitations that must be acknowledged. First, Markov models do not 
take into account resource constraints, such as treatment capacity, which extend the time 
required to treat all untreated patients with hepatitis C. To approximate the effects of treating 
patients over time, we estimated annual treatment probabilities for patients at each stage of the 
disease. Other analytic methods, such as discrete event simulation, may provide more precise 
estimates, but because our assumptions tended to bias the model against the full access strategy, 
the conclusions are likely to be similar. Second, our estimation of the Medicaid hepatitis C 
population size and treatment capacity are approximations based on the most recent published 
data from the Centers for Disease Control. To account for measurement error, we used an 
overestimate of the Medicaid hepatitis C population to derive conservative estimates in our 
sensitivity analyses. Third, our analysis does not include patient premiums or state financial 
contributions to the Medicaid program. This is unlikely to significantly impact our results; 
patient premiums would be constant for both treatment strategies and the federal government 
contributes up to 90% of the costs of state Medicaid programs, depending on their participation 
in Medicaid expansion (107). Fourth, because real-world effectiveness data were not available 
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for either medication regimen, we used efficacy data from recent clinical trials, which may 
overestimate treatment success rates. Finally, our model only included long-term costs related to 
liver disease. In fact, reducing early mortality may allow patients to live long enough to develop 
diseases of older age and paradoxically increase overall costs to the Medicare program. This 
concern is beyond the scope of this analysis but is an interesting topic for future study. 
In conclusion, using cost-effectiveness analyses, we found that the current Medicaid 
policy of restricting hepatitis C treatment to patients with advanced disease is more costly and 
less effective than providing open access to treatment for patients with early-stage disease as 
well. Although our results provide empiric support for providing open access to treatment for 
hepatitis C, additional factors, including the size of the physician workforce and budgetary 
limitations, must also be considered. Our results suggest that collaborative efforts between state 
and federal payers may be needed to achieve the maximum possible public health impact of 
novel hepatitis C medications. 
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4.0  DIFFERENCES IN PHYSICIAN REFERRAL DRIVE DISPARITIES IN 
SURGICAL INTERVENTION FOR HEPATOCELLULAR CARCINOMA  
4.1 BACKGROUND  
Hepatocellular carcinoma (HCC) is the second most common cause of cancer death worldwide 
(9). Although its incidence in the United States has more than tripled over the last 40 years, only 
modest improvements in survival have been made during that period (108). Currently, only 15% 
of patients live for five years or longer (109) and surgical interventions (radiofrequency ablation, 
resection or transplantation) are the only potentially curative treatment options (110-112). These 
interventions offer dramatic survival advantages over palliative therapies, but only 30-40% of 
patients with HCC actually receive such surgery (110, 113-115). 
Though sociodemographic factors are associated with use of surgical interventions for 
HCC (114-120), referral for surgery may be the most significant barrier. Referral for surgical 
intervention is a key step in the process between diagnosis with HCC and receipt of surgical 
intervention but has not been well studied. One recent study considered referral for surgery as a 
secondary outcome but did not identify factors independently associated with this outcome 
(121). Others have tried to understand referral for surgery by studying referral to a specialist. 
While patients referred to specialists are more likely to receive some form of treatment for HCC, 
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being seen by a specialist does not guarantee that an eligible patient will be offered a potentially 
curative surgery (122, 123). 
There is also evidence that geographic location may impact referral for and use of 
surgical intervention for HCC. Use of surgical intervention can vary based on rural location 
(rurality) and region of residence (114, 118). Regional differences could be attributed to 
differences in proximity to specialized cancer care, which affects the use of specialized treatment 
approaches for other types of cancer (124-130). The relationship between geographic location 
and referral for surgery has not been explored, but there are significant regional differences in 
specialist consultation for HCC, which may partially influence referral for surgery (123). 
In summary, the literature points to some important gaps in our understanding of surgical 
intervention for HCC. Even though referral is a prerequisite for receipt of surgery, few studies 
distinguish between factors affecting referral for surgery and factors affecting receipt of a 
recommended surgical intervention. Similarly, geographic factors, including rural residence or 
proximity to specialized care, may contribute to variations in surgical intervention for HCC but 
have not yet been explored. Our study aims were to determine whether sociodemographic and 
geographic factors, including proximity to a surgical center and rurality, are associated with 
referral for surgery and receipt of a recommended surgical intervention for HCC. 
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4.2 METHODS  
4.2.1 Design and Data Sources 
We conducted a retrospective cohort study using secondary data from the Pennsylvania Cancer 
Registry, Pennsylvania Health Care Cost Containment Council, and US Census Bureau. 
Pennsylvania Cancer Registry collects standardized information on all patients diagnosed with or 
treated for cancer in Pennsylvania and includes more than 95% of all new cancer cases. The 
Pennsylvania Health Care Cost Containment Council Database includes records from inpatient 
hospital visits at general acute care hospitals statewide and can be used to calculate hospital 
procedure volume. The US Census Bureau’s 2011 American Community Survey includes 
information about educational attainment and median household income. The 2010 Census 
includes information about rurality, defined as the percent of the population in a ZIP Code 
Tabulation Area (ZCTA) that resides in a rural area.1  The University of Pittsburgh Institutional 
Review Board approved this as an exempt study. 
4.2.2 Participants 
We included patients ages 18 and older who were diagnosed with HCC between January 1, 2006 
and December 31, 2011. During this period, there were no substantial changes to HCC treatment 
guidelines. At diagnosis, patients were residents of Pennsylvania or a geographically contiguous 
state. We excluded patients who were diagnosed with HCC at autopsy or using death certificates, 
                                                 
1 Because ZIP codes refer to United States Postal Service mailing routes, the US Census Bureau 
created a geographic representation called the ZCTA, which identifies the areas in which a given 
ZIP code is most prevalent. 
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had unknown treatment type or stage, or had contraindications for surgery in their Pennsylvania 
Cancer Registry record (e.g. based on age or comorbid conditions). 
4.2.3 Study Outcomes 
We used the Pennsylvania Cancer Registry to identify two outcomes: (1) referral for surgery for 
HCC and (2) receipt of surgical intervention. Surgical intervention was defined as liver resection, 
ablation, or transplantation. Because referral is a prerequisite for receiving surgery, patients in 
the latter analysis are a subset of those who were referred for surgery.  
4.2.4 Variables 
Our primary independent variables of interest were (1) proximity to a surgical center and (2) 
rurality. We defined proximity as residence within 30 minutes of a center that performed at least 
30 liver cancer-directed procedures annually (top quintile of hospital procedure volume) (131-
134). Hospitals where 30 or more hepatic resections are performed have significantly less 
morbidity and mortality than lower volume hospitals (131). Liver cancer-directed procedures 
were identified using Pennsylvania Health Care Cost Containment Council data and 
International Classification of Diseases, Ninth Revision, Clinical Modification procedure codes 
for liver resection, liver ablation, and liver transplantation. The twenty-six hospitals in 
Pennsylvania designated as surgical centers perform over 90% of liver cancer-directed 
procedures. These hospitals serve 19,000 to 326,000 patients each year and most are teaching 
hospitals located in large metropolitan areas. We then used ArcGIS 10 (ESRI, Redlands, CA) to 
map the location of surgical centers and the residence of patients with HCC at time of diagnosis. 
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Finally, we calculated travel time between the centroid of each patient’s home ZIP code and the 
nearest surgical center. We defined rurality as a continuous measure describing the proportion of 
rural (versus urban) residential housing within a specified geographic area. In the current 
analysis, it is expressed as the proportion of residents in the patient’s ZCTA living in rural areas 
according to 2010 Census data.  
We also abstracted patient demographic data (including age, race, sex, and primary 
medical insurance at diagnosis) and National Cancer Institute Statistics, Epidemiology and End 
Results Program (SEER) summary stage at diagnosis for all patients with HCC. We used 5-year 
estimates from the 2011 American Community Survey to identify median household income and 
educational attainment for each patient’s ZCTA.  
4.2.5 Primary Analyses 
We compared baseline patient characteristics for each outcome using the Wilcoxon rank sum test 
for continuous variables and chi-square or Fisher’s exact tests for categorical variables. We used 
logistic regression to assess the univariable associations between all independent and control 
variables and referral for and receipt of surgical intervention for HCC. We used multivariable 
logistic regression models to determine whether sociodemographic and geographic factors, 
including rurality and proximity, were associated with referral for surgical intervention or receipt 
of surgical intervention. We decided a priori to adjust multivariable models for known 
confounders, including patient age, race, sex, tumor stage, insurance type, income and 
educational attainment. To address potential collinearity in our multivariable models, we used 
Pearson correlation coefficients to evaluate pairwise relationships between predictor variables. 
For pairs of highly correlated variables (r >|0.5|), we included in the multivariable model the 
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predictor that was most strongly associated with the outcome variable. We derived odds ratios 
(ORs) and 95% confidence intervals (CIs) from univariable and multivariable logistic regression 
models, calculated variance inflation factors to identify further collinearity and evaluated all 
potential interactions between variables. We defined statistical significance as a two-tailed p-
value of less than 0.05. All statistical analyses were performed using Stata 13 (StataCorp, 
College Station, TX). 
4.2.6 Secondary Analyses 
We conducted sensitivity analyses for variables that were excluded from multivariable models 
due to collinearity. We identified significant collinearity between proximity to a surgical center 
and rurality (r=-0.51) and between income and educational attainment (r=0.67), so we included 
proximity and income in our multivariable models. We then conducted sensitivity analyses 
testing the effects of building the multivariable models using rurality instead of proximity to a 
surgical center or using educational attainment instead of income. 
We also identified determinants of proximity to a surgical center and rurality. We 
compared characteristics of patients living within 30 minutes of a surgical center with those 
living further away using the Wilcoxon rank sum test for continuous variables and chi-square test 
for categorical variables. Similarly, we identified factors associated with rurality using Pearson’s 
correlations for continuous variables, Wilcoxon rank-sum tests for binary variables, and Kruskal-
Wallis tests for other categorical variables. 
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4.3 RESULTS  
After identifying 4,560 case records for adults living in Pennsylvania or a contiguous state with a 
diagnosis of HCC in calendar years 2006 through 2011, we excluded patients with duplicate 
records (n=11), tumors of unknown stage (n=382), documented contraindications for surgery 
(n=360), or an uncertain course of treatment (n=230). The study cohort consisted of 3,576 unique 
patients with HCC. The mean patient age was 63.4 years (SD 11.5), 77.3% were male, and 
71.7% were non-Hispanic Caucasian (Table 4.1).  
A total of 1,466 (40.6%) patients were referred for surgery, of which 1,276 (87.0%) 
received a surgical intervention. The 190 patients who were referred but did not receive surgery 
either died before surgery could be performed (n=24), refused surgery (n=40), or did not undergo 
surgical intervention for unknown reasons (n=128).  
4.3.1 Referral for Surgery 
Patients referred (vs. not referred) for surgery were more often younger, Caucasian or Asian, and 
privately insured; they also had higher median income, educational attainment, and a greater 
frequency of localized disease (Table 4.2). In univariable analyses, patients living within 30 
minutes of a surgical center were significantly less likely to be referred for surgical intervention 
than those living farther away (OR: 0.76, 95% CI: 0.66-0.87) (Table 4.3). 
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Table 4.1 Demographic Characteristics of Patients Undergoing Surgical Intervention 
Characteristics All Patients (N=3,576) 
Demographic Characteristics 
Age in years Mean (SD) 63.5 (11.5) 
Male sex N (%) 2,765 (77.3) 
Race N (%) 
White 2,565 (71.7) 
African-American 653 (18.3) 
Hispanic 120 (3.4) 
Asian 163 (4.6) 
Other/Unknown 75 (2.1) 
Insurance Type N (%) 
Private 1,282 (35.9) 
Medicare 1,522 (42.6) 
Medicaid 470 (13.1) 
Other 302 (8.5) 
Income, $1000s Median (IQR) 48.5 (27.0) 
Percent high school graduates Median (IQR) 88.2 (9.0) 
Other Characteristics 
SEER summary stage N (%) 
Localized 1,979 (55.3) 
Regional 1,055 (29.5) 
Distant 542 (15.2) 
Proximity to high volume surgical center (<30 minutes) N (%) 2,230 (62.4) 
Rural residence Median (IQR) 0.4 (18.7) 
Abbreviations: IQR: interquartile range; N: number of patients; SD: standard deviation; 
SEER: National Cancer Institute Surveillance, Epidemiology and End Results program.   
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Table 4.2 Univariable Analyses of Factors Associated with Referral for Surgery for Hepatocellular Carcinoma 
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Table 4.3 Univariable Analyses of Factors Associated with Receipt of Surgery for Hepatocellular Carcinoma 
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In our multivariable logistic regression model, proximity to a surgical center was 
independently associated with 21% lower odds of referral for surgery (adjusted OR: 0.79, 95% 
CI: 0.68-0.92) (Table 4.4). Older age, male sex, Medicaid or other insurance, and regional or 
distant tumor stage at diagnosis were associated with a decreased frequency of surgical referral. 
Asian race was positively associated with referral for surgery. There were no significant 
differences in referral based on African-American, Hispanic, or “Other/Unknown” race, 
Medicare insurance, or median household income. There were no significant interactions 
between predictor variables and referral for surgery, including interactions between race and 
proximity to a surgical center (p>0.05 for all potential interactions). 
4.3.2 Receipt of Surgical Intervention 
Patients who received surgical intervention (vs. not receiving surgery) were less likely to have an 
“Other/Unknown” race/ethnicity and to have distant involvement of HCC (Table 4.3). Our 
univariable logistic regression model revealed no significant differences in receipt of surgery 
based on proximity to a surgical center (OR: 0.84, 95% CI: 0.62-1.15). In our multivariable 
logistic regression model (Table 4.4), proximity to a surgical center was not significantly 
associated with receipt of surgical intervention (adjusted OR: 0.84, 95% CI: 0.60, 1.15). Distant 
stage at diagnosis was negatively associated with receipt of surgical intervention. There were no 
significant differences in receipt of surgery based on age, sex, African-American, Hispanic or 
Asian race/ethnicity, insurance type, or median household income.  In this analysis, there were 
no significant interactions between predictor variables and receipt of surgical intervention; 
potential interactions between race and proximity to a surgical center were non-significant 
(p>0.05 for all potential interactions). 
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Table 4.4 Multivariable Analyses of Factors Associated with Referral for & Receipt of Surgical Intervention 
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4.3.3 Additional Analyses 
Our sensitivity analyses were conducted to determine the effects of replacing proximity to a 
surgical center with rurality or replacing income with educational attainment in our multivariable 
models. There were no substantial changes to the multivariable model for referral for surgery 
after either substitution or to the multivariable model for receipt of surgery after substituting 
educational attainment for income. However, while we found no significant association between 
proximity to a surgical center and receipt of surgery, rurality was associated with a significantly 
increased likelihood of receipt of surgery (OR: 2.10, 95% CI: 1.10, 4.00). 
Based on the results of our primary analyses, we identified factors associated with 
proximity to a surgical center and rurality. Patients who lived close to a surgical center were 
more often African-American or insured by Medicaid, and lived in ZCTAs with higher median 
incomes, lower educational attainment and decreased rurality (Table 4.5). There were no 
significant differences in proximity to a surgical center based on age, sex, or tumor stage. 
Rurality was negatively associated with African-American, Hispanic, or Asian race/ethnicity 
(p<.001), Medicaid insurance (p<.001), median household income (p=.03), and proximity to a 
surgical center (p<.001). There were no significant differences in rurality based on age (p=.61), 
sex (p=.59), tumor stage (p=.11), or educational attainment (p=.31). 
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Table 4.5 Characteristics of Patients with Hepatocellular Carcinoma, By Proximity to a High Volume Center 
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4.4 DISCUSSION 
In this retrospective cohort study of patients with hepatocellular carcinoma, we found that a 
number of non-clinical factors are associated with referral for surgery but that the vast majority 
of patients who were referred ultimately underwent surgical intervention. We also found that 
proximity to a surgical center was independently associated with decreased odds of referral for 
surgical intervention. 
Our results suggest that socioeconomic and geographic disparities in surgical intervention 
tend to occur when patients are evaluated for treatment. The published literature offers weak 
explanations for this phenomenon. A few studies have identified disparities in referral to a 
specialist (defined as an oncologist or surgeon) after diagnosis with HCC (122, 123), but 
specialist referral only partially accounted for variations in treatment type; specialist referral is 
neither necessary nor sufficient for a patient to be referred for surgery. We demonstrate that 
almost every patient who is referred for surgery ultimately undergoes surgical intervention, 
which suggests that referral to a specialist is not the only underlying factor. Some suggest that 
comorbidities and age may influence a physician’s choice of initial therapy for HCC, but our 
analysis excluded patients for whom documented contraindications to surgery existed. Referral 
for surgery is a result of both the physician’s decision to recommend and the patient’s decision to 
consider a potentially curative treatment. While racial and psychosocial disparities exist in 
refusal of HCC-directed surgery (121), we considered a patient to have been referred whether or 
not they declined to undergo surgical intervention. Unfortunately, few studies have specifically 
evaluated referral for surgery, so much remains unknown about the barriers and facilitators of the 
referral process. Further studies are required to understand referral for surgery. It is conceivable 
that urban patients may be more likely to experience certain psychosocial issues such as 
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healthcare mistrust and poor health literacy.  This could impact their likelihood of having an 
established relationship with a physician and of being referred for surgical intervention. These 
psychosocial issues could be identified and addressed in order to improve surgical referral and 
ultimately patient outcomes.  
Furthermore, our results suggest that geographic proximity to a surgical center may not 
translate into improved access to care. We could not control for rurality in our multivariable 
model (due to collinearity), but our post-hoc analysis revealed that proximity to a surgical center 
was a uniquely urban phenomenon. Urban residence has long been associated with low 
socioeconomic status and poor access to care, but we attempted to control for some of these 
factors using proxy measures of socioeconomic status. The fact that proximity to care is still 
independently associated with lower odds of referral for surgery suggests that there may be some 
unmeasured characteristics of urban patients that impede access to care. This idea is supported in 
part by the literature. For example, African-American patients tend to live in urban areas close to 
sources of healthcare, but report longer travel times than patients of other races (130, 134). This 
suggests that mode of transportation may be an important aspect of access to care for some urban 
patients, but not for their rural counterparts.  
The findings in our study are consistent with the published literature in certain ways. For 
example, we identified many of the same socioeconomic disparities in referral for surgery as 
have previously been identified for overall utilization of surgery and found similar rates of 
surgery (114-120). However, when we excluded patients who were not referred for surgery from 
the analysis, we no longer identified socioeconomic disparities. The few studies that have 
separately considered referral for and receipt of surgery have focused on refusal of surgical 
intervention, which is associated with older age, African-American race, advanced tumor stage, 
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and marital status (121). While our results differ, the previous study did not consider other 
reasons for which patients might not undergo surgery (e.g., patient preferences) and used data 
from 1985-2004, when different treatment options were available. 
Other aspects of our results differ significantly from those found in the published 
literature. For example, disparities in surgery for African-American patients have been uniformly 
identified (114-120), but African-American race was not significantly associated with referral for 
or receipt of surgery in our study. We found significant racial variations in referral for surgery in 
our univariable analysis, but these differences were no longer apparent in the adjusted model. 
However, our secondary analysis revealed that African-American patients were more likely to 
live close to surgical centers than to live further away. This suggests that racial disparities in 
surgery might be better explained by geographic factors such as proximity to a surgical center. 
Still, the population of patients near surgical centers was still predominantly White and tended to 
have higher median incomes, so it is unlikely that proximity is solely a function of race or 
socioeconomic status.  
We recognize that our study has some limitations. First, most patients who were referred 
for surgery went on to undergo surgical intervention, so our analysis may not have had sufficient 
power to identify significant differences in receipt of surgery. Second, income and educational 
attainment data were aggregated at the ZCTA level, which could obscure systematic differences 
from the population mean. However, it is common practice to abstract these data from the US 
Census when individual-level data are unavailable. Third, because we used an administrative 
database, we could not identify patient-level factors, including detailed comorbidity information 
or laboratory or radiographic data to quantify the severity of a patient’s underlying liver disease, 
which could impact the decision to refer a patient for surgery. Instead, we had to rely on a 
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variable that indicated that a patient had documented contraindications to surgical intervention, 
which we hoped would include patients whose background liver disease precluded possible 
surgical intervention. Fourth, we also could not identify delays in referral, which could affect 
patient outcomes. Finally, this analysis was conducted using data from patients in Pennsylvania 
and may not be generalizable to other geographic areas in the United States or to healthcare 
systems outside the US.  
Our study builds on previous health disparities research in treatment for hepatocellular 
carcinoma. A commonly used conceptual framework defines three stages of health disparities 
research: (1) detection, (2) understanding, and (3) reducing disparities (135). Our study 
addressed stage 2; we built upon the previous foundation of disparities research in HCC and 
aimed to further understand the underlying processes. Our findings suggest that future efforts to 
investigate disparities in HCC treatment may need to qualitatively assess barriers to surgical 
referral for urban populations and among physicians. Currently, surgical intervention offers 
patients with HCC the best chance at long-term survival, so it is important to identify barriers 
and design interventions to ensure broad, equitable access to potentially curative treatment for all 
eligible patients with HCC. 
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5.0  CONCLUSION 
The projects included in this dissertation aimed to evaluate current practices in the treatment of 
chronic liver diseases and hepatocellular carcinoma. We demonstrated that for two populations 
of patients with hepatitis C, including military Veterans and Medicaid beneficiaries, it is cost-
effective to treat patients with both early- and advanced-stage fibrosis with recently approved 
interferon-free regimens. By comparison, we found that relaxing restrictions on hepatitis C 
treatment in the Medicaid program can result in substantial reductions in morbidity, mortality, 
and long-term costs for both the Medicare program and the Centers for Medicare and Medicaid 
Services overall. Finally, we determined that, for patients who have developed hepatocellular 
carcinoma, socioeconomic and geographic disparities in the use of potentially curative surgical 
intervention are driven by differences in physician treatment recommendations. 
Our work makes strides toward the goal of interrupting the continuum of chronic liver 
disease (Figure 1.1).  The first two studies evaluated strategies for improving access to hepatitis 
C treatment, which would reduce the incidence of diseases further on the continuum, including 
cirrhosis and hepatocellular carcinoma, and ultimately reduce mortality. The third study revealed 
previously unidentified barriers to surgical intervention for patients with hepatocellular 
carcinoma. Because surgical intervention is the only potentially curative treatment option for 
these patients, effectively addressing nonclinical barriers to surgery may be an ideal method of 
improving survival.  
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The studies included in this dissertation highlight important issues for future study. For 
patients with hepatitis C, it will become important to maximize the impact of investments in new 
medication regimens. This can be accomplished by continued evaluation of strategies to expand 
the physician workforce available to treat hepatitis C, ensure adherence to medication regimens, 
and reduce the risk of reinfection. Furthermore, the framework we have used to consider these 
highly effective but extremely costly medications will become increasingly important as payers 
are faced with more and more exorbitant prices for breakthrough medications (136). For patients 
with hepatocellular carcinoma, it will be important to understand why physician 
recommendations vary based on nonclinical factors and evaluate barriers that may adversely 
impact access to care for urban patients despite their relative proximity to high volume centers. 
Perhaps more importantly, it is essential that efforts to document and understand healthcare 
disparities ultimately give rise to effective interventions to equitably distribute quality care and 
improve public health (137). 
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